CONAN: Controlled-replication ONcolytic AdeNovirus
Problem to be solved
Immunotherapy for cancer patients with solid tumors based on oncolytic viruses.
Market Opportunity
In Spain, the net 5-year cancer survival rate after first and second-line treatments is 55%, with a current incidence of 280,000 new cases diagnosed in 2022. Cancer patients and public health System will be benefited. Patent has been submitted (EP24382337) on 27/03/2024.
Technology
Our proposal involves the therapeutic use of mesenchymal cells that serve as carriers for an oncolytic adenovirus designed to selectively target and eliminate tumor cells while preserving healthy tissue (tumor-selective replication viruses).
Autors
Rafael Moreno, Ramon Alemany
Technology Readiness Level
TRL4
What are we looking for?
Codevelopment and/or licensing out opportunities